Works matching AU Bucelli, Cristina
Results: 47
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects
- Published in:
- Cancers, 2025, v. 17, n. 6, p. 1022, doi. 10.3390/cancers17061022
- By:
- Publication type:
- Article
Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.852158
- By:
- Publication type:
- Article
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 11, p. 1527, doi. 10.1080/0284186X.2021.1971292
- By:
- Publication type:
- Article
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients.
- Published in:
- Patient Preference & Adherence, 2022, v. 16, p. 2963, doi. 10.2147/PPA.S369326
- By:
- Publication type:
- Article
New Perspectives on Polycythemia Vera: From Diagnosis to Therapy.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 16, p. 5805, doi. 10.3390/ijms21165805
- By:
- Publication type:
- Article
Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.701604
- By:
- Publication type:
- Article
Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.637116
- By:
- Publication type:
- Article
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 5, p. 323, doi. 10.1016/j.clml.2024.01.008
- By:
- Publication type:
- Article
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases.
- Published in:
- Journal of Dermatology (John Wiley & Sons, Inc.), 2023, v. 50, n. 10, p. 1330, doi. 10.1111/1346-8138.16836
- By:
- Publication type:
- Article
Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 5, p. 1, doi. 10.1002/hon.3309
- By:
- Publication type:
- Article
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 1, p. 123, doi. 10.1002/hon.2808
- By:
- Publication type:
- Article
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.
- Published in:
- Case Reports in Hematology, 2017, p. 1, doi. 10.1155/2017/6167345
- By:
- Publication type:
- Article
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases.
- Published in:
- Clinical & Experimental Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1007/s10238-024-01441-w
- By:
- Publication type:
- Article
Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 6, p. 890, doi. 10.1111/bjh.13343
- By:
- Publication type:
- Article
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1462, doi. 10.1002/ajh.27418
- By:
- Publication type:
- Article
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1762, doi. 10.1002/ajh.27073
- By:
- Publication type:
- Article
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. E260, doi. 10.1002/ajh.25908
- By:
- Publication type:
- Article
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 11, p. E283, doi. 10.1002/ajh.25596
- By:
- Publication type:
- Article
Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 4, p. E47, doi. 10.1002/ajh.24656
- By:
- Publication type:
- Article
Anagrelide and Mutational Status in Essential Thrombocythemia.
- Published in:
- BioDrugs, 2016, v. 30, n. 3, p. 219, doi. 10.1007/s40259-016-0170-9
- By:
- Publication type:
- Article
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 3, p. 515, doi. 10.3390/jcm10030515
- By:
- Publication type:
- Article
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 5, p. 2041, doi. 10.1002/cam4.2087
- By:
- Publication type:
- Article
Prognostic and Predictive Models in Myelofibrosis.
- Published in:
- Current Hematologic Malignancy Reports, 2024, v. 19, n. 5, p. 223, doi. 10.1007/s11899-024-00739-6
- By:
- Publication type:
- Article
Comprehensive Molecular Analyses in a Case of Masked Philadelphia Chronic Myeloid Leukemia.
- Published in:
- Cytogenetic & Genome Research, 2016, v. 147, n. 1, p. 35, doi. 10.1159/000442039
- By:
- Publication type:
- Article
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 5, p. 475, doi. 10.1007/s40261-018-0623-7
- By:
- Publication type:
- Article
Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 4, p. 939, doi. 10.1002/cpt.2485
- By:
- Publication type:
- Article
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 12, p. 1720, doi. 10.1007/s11864-023-01149-1
- By:
- Publication type:
- Article
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 7, p. 802, doi. 10.1007/s11864-023-01099-8
- By:
- Publication type:
- Article
Management of Myelofibrosis: from Diagnosis to New Target Therapies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 17, p. 2637, doi. 10.1002/cncr.34923
- By:
- Publication type:
- Article
Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
- Published in:
- Histopathology, 2017, v. 71, n. 6, p. 897, doi. 10.1111/his.13309
- By:
- Publication type:
- Article
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1799, doi. 10.3390/cancers14071799
- By:
- Publication type:
- Article
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 207, doi. 10.1007/s00277-024-06100-4
- By:
- Publication type:
- Article
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2787, doi. 10.1007/s00277-024-05801-0
- By:
- Publication type:
- Article
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1409, doi. 10.1007/s00277-023-05217-2
- By:
- Publication type:
- Article
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
- Published in:
- Chemotherapy (0009-3157), 2018, v. 63, n. 6, p. 340, doi. 10.1159/000497246
- By:
- Publication type:
- Article
Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1012268
- By:
- Publication type:
- Article
Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.
- Published in:
- PLoS ONE, 2019, v. 14, n. 7, p. 1, doi. 10.1371/journal.pone.0218444
- By:
- Publication type:
- Article
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. e53, doi. 10.1111/bjh.18641
- By:
- Publication type:
- Article
Trend of circulating CD34<sup>+</sup> cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 3, p. 315, doi. 10.1111/bjh.18526
- By:
- Publication type:
- Article